In advanced melanoma, the potential prognostic value of CD3, CD8, CD20 and FOXP3 expression levels is being evaluated in patients treated with ipilimumab [66], and the correlation of marker expression profile with clinical outcome is ongoing. This evidence concerns the gene FOXP3 and melanoma.